Skip to main content

Roche Holdings Ltd ADR(RHHBY)
OTC US

Today's Change
Delayed Last Update
Volume

Latest News

Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older
Business Wire - Thu Aug 11, 2:40PM CDT
Business Wire
Thu Aug 11, 2:40PM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) for the treatment of...
Roche receives FDA approval for VENTANA MMR RxDx Panel to identify dMMR solid tumour patients and pMMR endometrial cancer patients eligible for KEYTRUDA
PR Newswire - Thu Aug 11, 12:00AM CDT
PR Newswire
Thu Aug 11, 12:00AM CDT
/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of a label expansion for the VENTANA MMR RxDx...
Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
Business Wire - Tue Aug 2, 12:00AM CDT
Business Wire
Tue Aug 2, 12:00AM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq ® (atezolizumab) met its co-primary endpoints. The study showed...
How This Multibillion-Dollar Company Is Shaking Off the Competition
Motley Fool - Sat Jul 30, 9:45AM CDT
Motley Fool
Sat Jul 30, 9:45AM CDT
The company has posted growth despite lower demand for several key products.
Genentech to Present Scientific Progress Across Alzheimer’s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting
Business Wire - Thu Jul 28, 12:00AM CDT
Business Wire
Thu Jul 28, 12:00AM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that data from 41 abstracts across its portfolio of Alzheimer’s disease pharmaceuticals and diagnostics will be presented at the 2022 Alzheimer’s Association...
New Two-Year Data Confirm Genentech’s Vabysmo Improves Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration
Business Wire - Thu Jul 14, 7:45AM CDT
Business Wire
Thu Jul 14, 7:45AM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new two-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo ® (faricimab-svoa) in wet, or...
New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
Business Wire - Mon Jul 11, 4:45AM CDT
Business Wire
Mon Jul 11, 4:45AM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the primary analysis of the Phase III HAVEN 6 study, which show that Hemlibra ® (emicizumab-kxwh) continued to demonstrate a favorable safety...
FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma
Business Wire - Wed Jul 6, 12:00AM CDT
Business Wire
Wed Jul 6, 12:00AM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for mosunetuzumab, a...
Landmark Alzheimer's Prevention Trial Unable to Show Significantly Slower Cognitive Decline in Inherited Form of Disease
PR Newswire - Thu Jun 16, 12:05AM CDT
PR Newswire
Thu Jun 16, 12:05AM CDT
/PRNewswire/ -- A precedent-setting prevention trial in Colombia has found that the investigational medicine crenezumab did not slow or prevent decline in...
Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
Business Wire - Thu Jun 16, 12:00AM CDT
Business Wire
Thu Jun 16, 12:00AM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimer’s Institute, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial....